Should Patients Be Switched to Another Insulin If There Is No Clear Advantage?

All insulins have slightly different properties

| Feb 1, 2006

The International Diabetes Federation (IDF), in its March 2005 position statement, stated that “All insulins have slightly different properties, and patients should not be changed from one to another insulin type unless there is a clear advantage.”

The IDF went on to say, “No insulin type will suit every patient, and it is important that variety is maintained in order to find the insulin that suits each patient best.”

We asked our experts what they thought about the IDF position statement.

“That pretty much makes sense. I took every one of my patients off NPH and switched them to Ultralente because there was a clear advantage. The only times I ever switch a person from Regular to Humalog is if during a correction they wanted to get their BG down fast; if their prediction of when they were going to eat a meal was uncertain; and if they had the type of job where they never know when they are going to eat. Those are all clear advantages. If something is working, you don’t mess with it unless there is an advantage.”

—Richard K. Bernstein, MD, FACE, FACN, FACCWS

“They should not be changed if it is going to create a problem. Sometimes you don’t know if there is an advantage for that patient until you do the switch. Lantus is an advantage for most patients as a basal, but you don’t know that until you make the switch.”

—Nancy Bohannon, MD, FACP, FACE

“An excellent statement! In the United States, insurance companies ignore this all the time, and not just for insulin, but for blood pressure medications, thyroid preparations, lipid medications, antidepressants. Cost is the major factor for Medicare, Medicaid and all other healthcare in the United States. I suspect that this is similar in other parts of the world, although rationing decisions are rarely discussed openly.”

—Stuart Brink, MD

“A clear advantage was created with studies that were specifically designed to make Lantus look far superior to Ultralente. The problem with these studies, when you read the fine print hidden within the research, was that Lantus was used in appropriate ways and then contrasted to inappropriately used Ultralente (and NPH). It is unfortunate that within the clinical and medical education setting, very few physicians or their patients were ever given an opportunity to understand and see how well Ultralente can work when it is used appropriately. Contrary to the opinions continually propagated as truth because of these poorly run studies, when Ultralente is used appropriately, it is a very predictable and stable basal insulin. For the diabetic trying to make sense of seemingly contradictory information, everything becomes more and more confusing. For the companies who are forcing changes, confusion has a secondary effect of neutralizing the motivation needed to initiate action against them. In context of the many long-term safety unknowns with the new synthetic “insulin analogues,” the loss of the only other stable basal insulin is tragic. Outside of the confusion game, the effects of the impending forced insulin changes will in actuality be a clear disadvantage for many diabetics.”

—Steven Gordon, ND

“The IDF statement is coming too late. What is the point of issuing that statement now, after the insulin companies have made decisions to remove first the animal insulins and now Lente and Ultralente? I can’t help asking: Why didn’t they make this statement five years ago?”

—Jenny Hirst

Click Here To View Or Post Comments

Categories: Diabetes, Diabetes, Insulin, Lantus, Type 1 Issues


Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • What's on the Horizon with Diabetes Research and Therapy
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Latest
Popular
Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Comments


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.